1
                                                                    EXHIBIT 99.2

FOR IMMEDIATE RELEASE

Contact:      Richard Harrison                      Rob Whetstone
              Vice President - Finance              Pondel Parsons & Wilkinson
              (949) 453-3200                        (310) 207-9300


               INTERPORE INTERNATIONAL AND CROSS MEDICAL PRODUCTS
                           COMPLETE MERGER TRANSACTION

IRVINE, Calif. -- May 7, 1998 -- Interpore International (Nasdaq NM: BONZ) and
Cross Medical Products (Nasdaq: CRSS) today announced the completion of their
previously announced merger, creating a combined medical device company offering
an expanded range of products to orthopaedic and neurosurgeons. Stockholders of
both companies overwhelmingly approved the merger transaction yesterday. The
company intends to operate under the name Interpore Cross International.

Pursuant to the merger agreement, a wholly-owned subsidiary of Interpore has
been merged with and into Cross, with Cross becoming a wholly-owned subsidiary
of Interpore. As a result of the merger, each share of Cross common stock has
been converted into the right to receive 1.275 shares of Interpore common stock.

David C. Mercer, Chairman and Chief Executive Officer of Interpore, said,
"Nearly three months after we announced our intention to merge, we are more
convinced than ever that this merger is an excellent fit for both companies. The
complementary strengths of each partner's product portfolio and the critical
mass achieved by the combination should bring greater value to all of our
shareholders."

Mercer added, "Our combined product portfolio of synthetic bone graft materials
and spinal implant systems is ideally positioned to benefit our customers,
shareholders and employees through cross-selling of our products, as well as
through synergies which we expect to realize from the combination of our
respective operations."

Joseph A. Mussey, the new President and Chief Operating Officer of Interpore,
said, "Because our companies shared a common vision and similar culture, we have
been able to move swiftly in integrating our organizations. We are currently
implementing programs to achieve cost savings in our newly combined corporate
support functions and distribution channels. The merger provides the combined
company with a critical mass which should enhance our growth potential in the
rapidly consolidating medical device industry."

                                    - more -



   2

Genesis Merchant Group Securities, L.L.C. served as financial advisor to
Interpore and Piper Jaffray Inc. served as financial advisor to Cross Medical in
connection with the merger.

Interpore also announced that, immediately prior to the Interpore/Cross merger,
Interpore completed its reincorporation from California to Delaware.

The combined company, Interpore Cross International (Nasdaq NM: BONZ), based in
Irvine, is a medical device company specializing in the development, manufacture
and marketing of synthetic bone and tissue products for use in the orthopaedic,
oral/maxillofacial and ophthalmic markets and the worldwide supply of spinal
implant devices used to treat degenerative conditions and deformities of the
spine.

Certain statements in this release are forward-looking and may involve risk and
uncertainties, including, but not limited to: risks that anticipated synergies
from the merger will not be realized; risks that the two companies cannot be
successfully integrated; product demand and market acceptance risks; the
development of future products; successful completion of clinical studies;
regulatory approval of new products; and the impact of competitive products.
Additional information on factors that could affect the company's financial
results and growth prospects is disclosed in the company's reports filed from
time to time with the Securities and Exchange Commission.

                                      # # #


98-5